Carsten Skarke

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/69610/publications.pdf

Version: 2024-02-01

60 papers	2,537 citations	236833 25 h-index	197736 49 g-index
63 all docs	63 docs citations	63 times ranked	2656 citing authors

#	Article	IF	Citations
1	Nitecap: An Exploratory Circadian Analysis Web Application. Journal of Biological Rhythms, 2022, 37, 43-52.	1.4	18
2	No increase in inflammation in late-life major depression screened to exclude physical illness. Translational Psychiatry, 2022, 12, 118.	2.4	9
3	Time-specific associations of wearable sensor-based cardiovascular and behavioral readouts with disease phenotypes in the outpatient setting of the Chronic Renal Insufficiency Cohort. Digital Health, 2022, 8, 205520762211079.	0.9	4
4	Guidelines for the design and conduct of human clinical trials on ingestion-time differences â€“ chronopharmacology and chronotherapy â€“ of hypertension medications. Chronobiology International, 2021, 38, 1-26.	0.9	22
5	Considerations for the Safe Operation of Schools During the Coronavirus Pandemic. Frontiers in Public Health, 2021, 9, 751451.	1.3	9
6	Diet-Epigenome Axis. Circulation Genomic and Precision Medicine, 2020, 13, e003129.	1.6	1
7	CMPF, a Metabolite Formed Upon Prescription Omega-3-Acid Ethyl Ester Supplementation, Prevents and Reverses Steatosis. EBioMedicine, 2018, 27, 200-213.	2.7	35
8	Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury. Molecular Metabolism, 2017, 6, 1395-1406.	3.0	103
9	A Pilot Characterization of the Human Chronobiome. Scientific Reports, 2017, 7, 17141.	1.6	70
10	Bioactive products formed in humans from fish oils. Journal of Lipid Research, 2015, 56, 1808-1820.	2.0	83
11	Selective COX-2 Inhibitors Suppress Prostacyclin. Clinical Therapeutics, 2014, 36, 2120-2121.	1.1	1
12	Non-invasive combined surrogates of remifentanil blood concentrations with relevance to analgesia. Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386, 865-873.	1.4	3
13	Enhanced absorption of boswellic acids by a lecithin delivery form (PhytosomeÂ®) of Boswellia extract. FÃ¬toterapÃ¬Ã¢, 2013, 84, 89-98.	1.1	101
14	GCG100649, A Novel Cyclooxygenaseâ€2 Inhibitor, Exhibits a Drug Disposition Profile in Healthy Volunteers Compatible With High Affinity to Carbonic Anhydraseâ€I/II: Preliminary Doseâ€“Exposure Relationships to Define Clinical Development Strategies. Clinical Pharmacology in Drug Development, 2013, 2, 379-386.	0.8	10
15	Catching a Glimpse of Gut Bacteriaâ€“Drug Interactions. Science Translational Medicine, 2013, 5, .	5.8	0
16	Bioinspired Glue for Healing Atherosclerotic Plaques. Science Translational Medicine, 2013, 5, .	5.8	0
17	Insights into Aging Vessels. Science Translational Medicine, 2013, 5, .	5.8	0
18	Myrtucommulone from Myrtus communis: Metabolism, Permeability, and Systemic Exposure in Rats. Planta Medica, 2012, 78, 1932-1938.	0.7	10

#	Article	IF	Citations
19	Comparative Impact on Prostanoid Biosynthesis of Celecoxib and the Novel Nonsteroidal Anti-Inflammatory Drug CG100649. Clinical Pharmacology and Therapeutics, 2012, 91, 986-993.	2.3	16
20	Increased Bioavailability of 11â€Ketoâ€Î²â€Boswellic Acid Following Single Oral Dose Frankincense Extract Administration After a Standardized Meal in Healthy Male Volunteers: Modeling and Simulation Considerations for Evaluating Drug Exposures. Journal of Clinical Pharmacology, 2012, 52, 1592-1600.	1.0	53
21	Obesity: Itâ€™s (Kind of) Genetic. Science Translational Medicine, 2012, 4, .	5.8	1
22	A Painful Question of Metabolism. Science Translational Medicine, 2012, 4, .	5.8	0
23	You May Feel Some Discomfortâ€”or Not!. Science Translational Medicine, 2012, 4, .	5.8	0
24	May the Resolvins Be with Youâ€¦. Science Translational Medicine, 2012, 4, .	5.8	0
25	Getting to the Root of SLOS. Science Translational Medicine, 2012, 4, .	5.8	0
26	Selected Microbes Light the Flame. Science Translational Medicine, 2012, 4, .	5.8	0
27	How Much Alcohol Is Too Much?. Science Translational Medicine, 2012, 4, .	5.8	0
28	A Mechanism of Interest as We Grow Older. Science Translational Medicine, 2012, 4, .	5.8	0
29	"Honey, Have You Taken Your Polyphenols Today?". Science Translational Medicine, 2012, 4, .	5.8	0
30	Dissecting the Mystery Around Multiple Sclerosis. Science Translational Medicine, 2012, 4, .	5.8	1
31	Training Translators for Smart Drug Discovery. Science Translational Medicine, 2010, 2, 26cm12.	5.8	20
32	Identification of Human Cathepsin G As a Functional Target of Boswellic Acids from the Anti-Inflammatory Remedy Frankincense. Journal of Immunology, 2009, 183, 3433-3442.	0.4	72
33	On the interference of boswellic acids with 5-lipoxygenase: Mechanistic studies in vitro and pharmacological relevance. European Journal of Pharmacology, 2009, 606, 246-254.	1.7	51
34	Pyrosequencingâ„¢ of polymorphisms in the COX-2 gene (PTGS2) with reported clinical relevance. Pharmacogenomics, 2007, 8, 1643-1660.	0.6	19
35	Effects of selective COXâ€2 inhibition on prostanoids and platelet physiology in young healthy volunteers. Journal of Thrombosis and Haemostasis, 2007, 5, 2376-2385.	1.9	47
36	Evidence for morphine-independent central nervous opioid effects after administration of codeine: Contribution of other codeine metabolites. Clinical Pharmacology and Therapeutics, 2006, 79, 35-48.	2.3	68

#	Article	IF	Citations
37	Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clinical Pharmacology and Therapeutics, 2006, 79, 72-89.	2.3	91
38	The cyclooxygenase 2 genetic variant â^'765G›C does not modulate the effects of celecoxib on prostaglandin E2 production. Clinical Pharmacology and Therapeutics, 2006, 80, 621-632.	2.3	30
39	Rapid identification of three functionally relevant polymorphisms in the OATP1B1 transporter gene using Pyrosequencingâ„¢. Pharmacogenomics, 2006, 7, 167-176.	0.6	10
40	The 5-hydroxytryptamine 4 receptor agonist mosapride does not antagonize morphine-induced respiratory depression. Clinical Pharmacology and Therapeutics, 2005, 78, 278-287.	2.3	45
41	Rapid genotyping for relevant CYP1A2 alleles by pyrosequencing. European Journal of Clinical Pharmacology, 2005, 61, 887-892.	0.8	33
42	Is morphine-3-glucuronide of therapeutic relevance?. Pain, 2005, 116, 177-180.	2.0	21
43	Comprehensive Mu-Opioid-Receptor Genotyping by Pyrosequencing. Clinical Chemistry, 2004, 50, 640-644.	1.5	28
44	Genetic Predictors of the Clinical Response to Opioid Analgesics. Clinical Pharmacokinetics, 2004, 43, 983-1013.	1.6	230
45	Probenecid Interacts with the Pharmacokinetics of Morphine-6-glucuronide in Humans. Anesthesiology, 2004, 101, 1394-1399.	1.3	22
46	Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clinical Pharmacology and Therapeutics, 2003, 73, 107-121.	2.3	187
47	Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine. Clinical Pharmacology and Therapeutics, 2003, 74, 303-311.	2.3	59
48	Pharmacokinetics of morphine are not altered in subjects with Gilbert's syndrome. British Journal of Clinical Pharmacology, 2003, 56, 228-231.	1.1	19
49	Simultaneous screening for three mutations in the ABCB1 gene. Genomics, 2003, 82, 503-510.	1.3	19
50	Olfactory Function in Mild Cognitive Impairment and Alzheimerâ€™s Disease: An Investigation Using Psychophysical and Electrophysiological Techniques. American Journal of Psychiatry, 2003, 160, 1995-2002.	4.0	152
51	Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics and Genomics, 2003, 13, 651-660.	5.7	106
52	The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics and Genomics, 2002, 12, 3-9.	5.7	201
53	Does the A118G Polymorphism at the Î¼-opioid Receptor Gene Protect against Morphine-6-Glucuronide Toxicity?. Anesthesiology, 2002, 97, 814-819.	1.3	149
54	Drug Interactions with Patient-Controlled Analgesia. Clinical Pharmacokinetics, 2002, 41, 31-57.	1.6	51

#	Article	IF	Citations
55	The influence of inhibition of probenecid sensitive transporters on the central nervous system (CNS) uptake and the antinociceptive activity of morphine-6-glucuronide in rats. Neuroscience Letters, 2002, 329, 145-148.	1.0	13
56	Morphine metabolites: Clinical implications. Seminars in Anesthesia, 2002, 21, 258-264.	0.3	5
57	Pharmacokinetic modeling to predict morphine and morphine-6-glucuronide plasma concentrations in healthy young volunteers*. Clinical Pharmacology and Therapeutics, 2002, 72, 151-162.	2.3	65
58	Effects of the opioid remifentanil on olfactory function in healthy volunteers. Life Sciences, 2001, 69, 2279-2285.	2.0	21
59	The Transfer Half-life of Morphine-6-glucuronide from Plasma to Effect Site Assessed by Pupil Size Measurement in Healthy Volunteers. Anesthesiology, 2001, 95, 1329-1338.	1.3	120
60	A rapid screening method for a single nucleotide polymorphism (SNP) in the human MOR gene. British Journal of Clinical Pharmacology, 2001, 52, 711-714.	1.1	24